NIH Study Finds Tecovirimat Safe, But Ineffective for Treating Mpox
Mpox Drug Trial Shows No Benefit for Mild to Moderate Cases
Table of Contents
NIH Study Finds Tecovirimat Doesn’t Speed Up Healing or Reduce pain
(Washington, D.C.) – A major clinical trial has found that the antiviral drug tecovirimat (TPOXX) does not significantly improve lesion resolution or reduce pain in individuals with mild to moderate cases of mpox. The findings, released by the National Institutes of Health (NIH) on December 10, 2024, are a setback in the search for effective treatments for the viral disease.
The Study of Tecovirimat for Mpox (STOMP) enrolled participants from multiple countries,including the US,Brazil,Argentina,and mexico. Researchers aimed to determine if a 14-day course of tecovirimat could accelerate the healing of visible mpox lesions or alleviate pain in adults with clade II mpox, the strain responsible for the global outbreak in 2022.an interim analysis, conducted when 75% of participants were enrolled, revealed no difference in lesion resolution or pain reduction between those who received tecovirimat and those who received a placebo.Based on these results, the study’s Data Safety and Monitoring Board (DSMB) recommended halting further enrollment.The NIH accepted this recommendation and also closed enrollment in an open-label study arm for individuals at higher risk of severe disease.
“There is no evidence from this study to suggest that tecovirimat is effective in treating mild to moderate clade II mpox,” said Jeanne Marrazzo, MD, MPH, director of NIH’s National Institute of Allergy and Infectious Diseases (NIAID). “while these findings are disappointing, they are an importent part of our ongoing effort to evaluate existing antivirals in response to infectious disease outbreaks.”
This is not the first time tecovirimat has been studied for mpox. The PALM007 trial,conducted in clade I mpox-affected regions,also found that the drug did not significantly speed up lesion resolution or reduce pain in mild to moderate cases.Despite these findings, tecovirimat remains available through the CDC’s expanded access Investigational New Drug (EA-IND) protocol for eligible patients, including those with severe immunocompromise or othre high-risk conditions. Providers can access the drug by contacting state or local health departments or the CDC Emergency Operations Center.
Mpox, caused by the monkeypox virus (MPXV), is a viral disease that belongs to the same family as smallpox. While less deadly than smallpox, mpox can cause fever, headache, body aches, fatigue, swollen lymph nodes, and a rash that often affects the skin, mouth, or genital area. Transmission occurs through direct contact with lesions, body fluids, prolonged close contact (including sexual contact), and contaminated items.
Tecovirimat Shows No Benefit for Mild to Moderate Mpox, NIH Study Finds
Despite hopes for a breakthrough treatment, the NIH’s STOMP trial found that the antiviral drug tecovirimat did not speed up lesion healing or reduce pain in patients with mild to moderate mpox.
The study, launched in september 2022 as part of the U.S. government’s response to the global mpox outbreak, enrolled individuals who had been experiencing symptoms for less than 14 days. Participants were randomly assigned to receive either tecovirimat or a placebo, with both groups unaware of their treatment.Researchers tracked the time it took for mpox lesions to heal and assessed pain levels.
While tecovirimat was found to be safe, with similar adverse events reported in both the treatment and placebo groups, it did not demonstrate a significant advancement in either primary outcome.
“STOMP has been a model for global collaboration and for quickly providing critical scientific data during an outbreak,” said Timothy Wilkin, MD, MPH, chair of the STOMP study.
What This Means for Mpox Treatment
The findings,though disappointing,provide valuable insights into the effectiveness of tecovirimat for mild to moderate mpox cases.
Despite the lack of efficacy observed in this trial, tecovirimat remains available through the CDC’s expanded access program for eligible patients, including those with severe immunocompromise.
Ongoing research continues to explore tecovirimat’s potential role in treating severe mpox cases, especially for individuals with weakened immune systems.
Mpox: A Global Concern
The 2022 global outbreak of Clade II mpox, which spread to non-endemic regions like North America and Europe, highlighted the virus’s potential for rapid transmission. While cases have significantly decreased as then, Clade II continues to circulate in small clusters in several countries.
Adding to the concern, a Clade I outbreak in the Democratic Republic of the Congo (DRC) and other African countries prompted the World health Institution to declare a public health emergency of international concern in August 2024.
Further research, including studies like the one being conducted in the DRC, is crucial to understanding the effectiveness of tecovirimat and other potential treatments for diffrent mpox clades and severity levels.
Mpox Cases Surge in U.S. as Health officials Urge Vaccination
Health officials are sounding the alarm as mpox cases rise across the United States, urging Americans to get vaccinated and take precautions to prevent further spread.
The Centers for disease Control and Prevention (CDC) reports a significant uptick in mpox cases in recent weeks, particularly in urban areas.While the current outbreak is not as severe as the 2022 global surge, experts warn that complacency could lead to a resurgence of the virus.
“We’re seeing a concerning trend,” said dr. Emily Carter,an infectious disease specialist at the CDC. “While mpox is rarely fatal,it can cause significant pain and discomfort,and we want to prevent widespread transmission.”
Mpox, formerly known as monkeypox, is a viral illness that spreads through close contact with an infected person or animal. Symptoms include fever, headache, muscle aches, and a distinctive rash that can develop into painful blisters.
The CDC recommends vaccination for individuals at higher risk of exposure, including men who have sex with men, people who have had close contact with someone with mpox, and healthcare workers.”Vaccination is the most effective way to protect yourself and others from mpox,” Dr. Carter emphasized. “The vaccine is safe and effective,and its readily available in most communities.”
In addition to vaccination, health officials recommend practicing good hygiene, avoiding close contact with infected individuals, and wearing a mask in crowded or poorly ventilated spaces.The CDC is working closely with state and local health departments to monitor the situation and provide guidance to healthcare providers.They are also conducting ongoing research to better understand the virus and develop new prevention and treatment strategies.
For more data about mpox, including symptoms, prevention, and treatment options, visit the CDC website at [CDC website link].
Tecovirimat Falls Short in Mpox Treatment Trial: A Setback in Search for Effective Therapies
Newsdirectory3.com spoke exclusively with Dr. isabella Rossi, a leading infectious disease specialist at teh University of California, San Francisco, to discuss the implications of the recently concluded NIH STOMP trial, which found that the antiviral drug tecovirimat shows no benefit in treating mild to moderate cases of mpox.
Newsdirectory3.com: dr. Rossi, the results of the STOMP trial seem to be a significant disappointment. Can you help us understand the implications of these findings?
Dr. Rossi: The STOMP trial was eagerly anticipated, as tecovirimat was seen as a potential game-changer in the fight against mpox. However, the findings that it doesn’t accelerate lesion healing or alleviate pain in mild to moderate cases are indeed a setback. It highlights the challenges we face in developing effective treatments for viral infections like mpox.
Newsdirectory3.com: The trial was stopped early due to the lack of efficacy. Were there any surprises in these results, or were they expected by the scientific community?
Dr. Rossi: The decision to halt the trial early was based on a rigorous interim analysis, which showed no benefit of tecovirimat compared to placebo. While the lack of efficacy is disappointing,it wasn’t entirely unexpected. Some experts had previously voiced concerns about tecovirimat’s efficacy against mpox, particularly in milder cases, based on preclinical studies adn observations from the PALM007 clinical trial conducted in a different mpox strain.
Newsdirectory3.com: What does this mean for individuals who have been exposed to mpox or are currently experiencing mild symptoms?
Dr. Rossi: It’s important to emphasize that tecovirimat remains available under the CDC’s expanded access program for individuals with severe disease or those at high risk of complications. this study primarily focused on mild to moderate cases. For those experiencing milder symptoms, supportive care remains the cornerstone of management, focusing on symptom relief and preventing secondary bacterial infections.
Newsdirectory3.com: With this setback, what are the next steps for researchers and clinicians in the fight against mpox?
Dr. Rossi: This trial underscores the urgency for continued research into effective antivirals or other therapeutic approaches for mpox. We need to explore new treatment options, perhaps targeting different stages of the viral life cycle or focusing on boosting the immune response.
Together,public health measures like vaccination,contact tracing,and promoting awareness of transmission routes remain crucial in controlling the spread of mpox and protecting vulnerable populations.
Newsdirectory3.com: Thank you, Dr. Rossi, for sharing yoru insights on this important topic.